Search
CRISPR Therapeutics AG
CRSPAdd to Watchlist
47.640USD
+0.090+0.19%
Close 07-29 16:00（ET）Quotes delayed by 15 min
4.59BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-29The current earnings forecast score of CRISPR Therapeutics AG is 7.48, ranking 291 out of 384 in the Biotechnology & Medical Research industry. The average price target is 74.50, with a high of 268.00 and a low of 32.00.
Analyst Rating
Based on
24
analysts
Buy
Current Rating
82.526
Target Price
+76.60%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
CRISPR Therapeutics AG
CRSP
24
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is CRISPR Therapeutics AG's expected revenue for the next quarter?
CRISPR Therapeutics AG's expected revenue is 6.79M.
What is CRISPR Therapeutics AG's price target?
Analysts forecast that CRISPR Therapeutics AG's price target is USD 74.50, with the highest forecast at USD 268.00 and the lowest forecast at USD 32.00.
How have CRISPR Therapeutics AGCRSP's recent earnings per share performed?
The market expectation was USD -1.28, while CRISPR Therapeutics AGCRSP's earnings per share (EPS) for the previous quarter was USD -1.37. EPS for the next quarter is expected at USD -1.20.
What is the analyst rating for CRISPR Therapeutics AG?
Based on the ratings of CRISPR Therapeutics AG's stock from 24 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.